Back to results
US 2017/0368166 A1Published application
Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers
AssigneeQu Biologics Inc.
InventorHarold David Gunn
Life of this patent
Estimating the term…
Abstract
The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.
Claims21
1-97. (canceled)
A method for treating a human patient for a cancer situated in a lung tissue, the method comprising:
- administering to the patient a medicament comprising an effective amount of an antigenic composition comprising antigenic determinants characteristic of Klebsiella pneumoniae, the antigenic determinants together being specific for Klebsiella pneumoniae so that the composition elicits an immune response in the patient that is specific for Klebsiella pneumoniae.
A method for treating a human patient for a cancer situated in a lung tissue, the method comprising:
- administering to the patient a medicament comprising an effective amount of an antigenic composition comprising antigenic determinants characteristic of Klebsiella pneumoniae, the antigenic determinants together being specific for Klebsiella pneumoniae so that the composition elicits an immune response in the patient that is specific for Klebsiella pneumoniae;
- administering the medicament in successive doses given at a dosage interval of between one hour and one month, over a dosage duration of at least two weeks in an amount and for a time that is effective to modulate an immune response, and the modulation of the immune response comprises a shift in the activation state of macrophages from a M2-like macrophage response to a M1-like macrophage response;
- and,
- administering to the patient an effective amount of cisplatin.
1 more element
Dependencies are inferred from the claim text.